Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery

Journal of Urology

Volumn 185, Issue 4, 2011, Pages 1268-1273

  Mondul, Alison M ^a   Han, Misop ^b   Humphreys, Elizabeth B ^b   Meinhold, Cari L ^a   Walsh, Patrick C ^b   Platz, Elizabeth A ^a,b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

hydroxymethylglutaryl CoA reductase inhibitors; local; neoplasm recurrence; prostate; prostatectomy; prostatic neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER GRADING; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CHEMOPROPHYLAXIS; DIGITAL RECTAL EXAMINATION; DRUG USE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 79952702672     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.11.089     Document Type: Article

References (22)

1. Shannon J, Tewoderos S, Garzotto M et al: Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005; 162: 318.
2. Platz EA, Leitzmann MF, Visvanathan K et al: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819.
3. Flick ED, Habel LA, Chan KA et al: Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218.
4. Jacobs EJ, Rodriguez C, Bain EB et al: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213.
5. Murtola TJ, Tammela TL, Lahtela J et al: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226.
6. Friedman GD, Flick ED, Udaltsova N et al: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 2008; 17: 27.
7. Agalliu I, Salinas CA, Hansten PD et al: Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250.
8. Boudreau DM, Yu O, Buist DS et al: Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008; 19: 767.
9. Coogan PF, Rosenberg L and Strom BL: Statin use and the risk of 10 cancers. Epidemiology 2007; 18: 213.
10. Friis S, Poulsen AH, Johnsen SP et al: Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643.
11. Kaye JA and Jick H: Statin use and cancer risk in the General Practice Research Database. B Br J Cancer 2004; 90: 635.
12. Rijo Mora E, Lorente Garin JA, Bielsa Gali O et al: The impact of statins use in clinically localized prostate cancer treated with radical prostatectomy. Actas Urol Esp 2009; 33: 351.
13. Loeb S, Kan D, Helfand BT et al: Is statin use associated with prostate cancer aggressiveness? BJU Int 2009; 105: 1222.
14. Gutt R, Tonlaar N, Kunnavakkam R et al: Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28: 2553.
15. Moyad MA, Merrick GS, Butler WM et al: Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006; 26: 298.
16. Soto DE, Daignault S, Sandler HM et al: No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73: 158.
17. Hamilton RJ, Banez LL, Aronson WJ et al: Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116: 3389.
18. Kollmeier MA, Katz MS, Mak K et al: Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys, Epub ahead of print May 6, 2010.
19. Krane LS, Kaul SA, Stricker HJ et al: Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183: 118.
20. Demierre MF, Higgins PD, Gruber SB et al: Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930.
21. Hamilton RJ and Freedland SJ: Rationale for statins in the chemoprevention of prostate cancer. Curr Urol Rep 2008; 9: 189.
22. Makarov DV, Trock BJ, Humphreys EB et al: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095.